

# WEST Search History

DATE: Tuesday, November 25, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
			result set
<i>DB=USPT,PGPB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L8	l5 and acylation	21	L8
L7	l6 and acylation	1	L7
L6	l5 and (sodium nitrite or sodium carbonite or sodium phosphate)	73	L6
L5	l1 same high salt	427	L5
L4	L3 and acylation	1732	L4
L3	l1 and (sodium nitrite or sodium carbonite or sodium phosphate)	11071	L3
L2	L1 same fish spermatogonium	0	L2
L1	(isolat\$ or purif\$) near3 (DNA or nucleic acid)	60343	L1

END OF SEARCH HISTORY

\$%^STN;HighlightOn= \*\*\*,HighlightOff=\*\*\* ;

Welcome to STN International! Enter x:x

LOGINID:ssspta1633cxq

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/Caplus records now contain indexing from 1907 to the present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003  
NEWS 5 AUG 13 Field Availability (IFA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:35:38 ON 25 NOV 2003

=> FIL BIOSIS EMBASE CAPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'BIOSIS' ENTERED AT 16:35:43 ON 25 NOV 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:35:43 ON 25 NOV 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:35:43 ON 25 NOV 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (isolat? or purif?) (3a) DNA  
L1 65109 (ISOLAT? OR PURIF?) (3A) DNA

=> s l1 and fish spermatogonium  
L2 0 L1 AND FISH SPERMATOGENON

=> s l1 and fish sperm?  
L3 0 L1 AND FISH SPERMAT?

=> s l1 and spermat?  
L4 2314 L1 AND SPERMAT?

=> s l4 and (sodium nitrite or sodium carbonite or sodium phosphate)  
L5 1 L4 AND (SODIUM NITRITE OR SODIUM CARBONITE OR SODIUM PHOSPHATE)

=> d bib abs

L5 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

AN 1976:232825 BIOSIS

DN PREV197662062825; BA62:62825

TI ATTEMPTS TO DETECT AGROBACTERIUM-TUMEFACIENS DNA IN CROWN GALL TUMOR TISSUE.

AU MERLO D J; KEMP J D

SO Plant Physiology (Rockville), (1976) Vol. 58, No. 1, pp. 100-106.

CODEN: PLPHAY. ISSN: 0032-0889.

DT Article

FS BA

LA Unavailable

AB Primary and secondary crown gall tissue cultures were established from sunflower plants (*Helianthus annuus*, cv. 'Mammoth Russian') wound-inoculated with *A. tumefaciens* (Smith and Townsend) Conn strain B6. Growth rates of tumor tissues and habituated healthy sunflower stem section tissues on basal medium lacking auxin and cytokinin were compared to those of healthy sunflower stem section tissue grown on the same medium with added phytohormones. No difference was detected in the thermal denaturation midpoints (74.8.degree. C) and melting profiles in 25 mM

\*\*\*sodium\*\*\* \*\*\*phosphate\*\*\* (pH 6.8), or the buoyant densities in cesium chloride equilibrium centrifugation (1.667 g cm-3), between

\*\*\*DNA\*\*\* \*\*\*isolated\*\*\* from crude nuclear preparations of the 4 tissue types. No satellite DNA was observed in equilibrium centrifugation of unsheared plant DNAs. Heterologous DNA renaturation kinetic analyses were performed in 0.14 M \*\*\*sodium\*\*\* \*\*\*phosphate\*\*\* (pH 6.8) at 70.degree. C. Thermal stability measurements of reassociated DNA revealed less than 1% of mismatched base pairs. Reannealing of sheared, denatured, radioactive *A. tumefaciens* B6 DNA (MW, 325,000 daltons) in the presence of a 5400-fold excess of sheared calf thymus, healthy tissue, or secondary sunflower crown gall DNA obeyed 2nd order kinetics, with a Cot1/2 [nucleotide concentration times incubation time] of 2.8, identical to that observed when B6 DNA was reannealed in the absence of foreign DNA. Reannealing rates of B6 DNA in the presence of 5400-fold excesses of DNA from 2 lines of primary sunflower crown gall were increased 2.24- or 1.47-fold. Digestion of the tumor DNA preparations with pancreatic DNase I until no detectable DNA remained, followed by restoration of solution viscosity by added calf thymus DNA, failed to remove the acceleration effect of the tumor DNA preparations. Reisolation of the reannealed nucleic acid formed in this experiment, and digestion with RNase A or DNase I revealed that the double-stranded fraction was composed entirely of DNA-DNA duplexes, with no detectable DNA-RNA hybrids. Tumor, but not healthy tissue DNA preparations contain some factor or factors (not DNA) which accelerate the reannealing of bacterial DNA. Sunflower tumor tissue DNAs, therefore, do not contain integrated *A. tumefaciens* DNA sequences in amounts greater than a random 1/5 of the bacterial genome per diploid amount of plant DNA, or a complete bacterial genome per 5 diploid plant cell DNA equivalents. The possibility of the presence of many copies of a specific portion greater than 5% of the bacterial genome is excluded.

=> d his

(FILE 'HOME' ENTERED AT 16:35:38 ON 25 NOV 2003)

FILE 'BIOSIS, EMBASE, CAPLUS' ENTERED AT 16:35:43 ON 25 NOV 2003

L1 65109 S (ISOLAT? OR PURIF?) (3A) DNA

L2 0 S L1 AND FISH SPERMATOGENON

L3 0 S L1 AND FISH SPERMAT?

L4 2314 S L1 AND SPERMAT?

L5 1 S L4 AND (SODIUM NITRITE OR SODIUM CARBONITE OR SODIUM PHOSPHATE)

=> s l4 and acylation

L6 0 L4 AND ACYLATION

=> s l1 and acylation

L7 20 L1 AND ACYLATION

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 16 DUP REM L7 (4 DUPLICATES REMOVED)

=> s l6 and high salt

L9 0 L6 AND HIGH SALT

=> s l8 and high salt

L10 0 L8 AND HIGH SALT

=> d bib abs l8 1-

YOU HAVE REQUESTED DATA FROM 16 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

AN 2003:134552 BIOSIS

DN PREV200300134552

TI Synthesis of long-chain fatty acid enol esters \*\*\*isolated\*\*\* from an environmental \*\*\*DNA\*\*\* clone.

AU Brady, Sean F. [Reprint Author]; Clardy, Jon [Reprint Author]

CS Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY, 14853-1301, USA

jcc12@cornell.edu

SO Organic Letters, (January 23, 2003) Vol. 5, No. 2, pp. 121-124. print.  
ISSN: 1523-7060 (ISSN print).

DT Article

LA English

ED Entered STN: 12 Mar 2003

Last Updated on STN: 12 Mar 2003

AB Long-chain fatty acid enol ester 1 is the major metabolite of a new family of small molecules isolated from the heterologous expression of environmentally derived DNA. A versatile synthesis of 1, in which an aromatic acetaldehyde is O-acylated with a long-chain acyl chloride allowed for the rapid construction of both the isolated product (1) and a number of structural analogues (including 8, 17, and 18).

L8 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2001:868644 CAPLUS

DN 136:17259

TI Purification, characterization and use of inulosucrase and levansucrase from Lactobacillus reuteri

IN Van Geel-Schutten, Gerritina Hendrika; Rahaoui, Hakim; Dijkhuizen, Lubbert; Van Hijum, Sacha Adrianus Fokke Taco  
PA Nederlandse Organisatie Voor Toegepast-Wetenschappelijk Onderzoek, Neth.

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001090319 A2 20011129 WO 2001-NL392 20010523  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
UZ, VN, YU, ZA, ZV, AM, AZ, BY, KG, KZ, MD, RU, TU, TM  
RW: GH, GM, KE, LS, MV, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1283888 A2 20030219 EP 2001-934630 20010523  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI EP 2000-201872 A 20000525

EP 2001-200049 A 20010109

WO 2001-NL392 W 20010523

AB The present invention describes two novel proteins having fructosyltransferase activity. One of the enzymes is an inulosucrase which produces an inulin and fructo-oligosaccharides, while the other is a levansucrase which produces a levan. Both enzymes are derived from Lactobacillus reuteri, which are food-grade microorganisms with the Generally Recognized As Safe (GRAS) status. \*\*\*Isolation\*\*\* of \*\*\*DNA\*\*\* from L. reuteri, nucleotide sequence anal. of the inulosucrase (iftA) gene, construction of plasmids for expression of the inulosucrase gene in E. coli Top10, expression of the inulosucrase gene in E. coli Top10 and identification of the polysaccharides produced by the recombinant enzyme are described. Purifn. and amino acid sequencing of the L. reuteri levansucrase (gene iftB) and nucleotide sequence of the gene iftB are reported. According to the invention lactobacilli capable of producing an inulin and/or a levan and/or fructo-oligosaccharides using one or both of the fructosyltransferases can be used as a probiotic or a symbiotic.

L8 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:545718 CAPLUS

DN 135:149588

TI Method of affinity purifying proteins using modified bis-arsenical fluorescein

IN Vale, Ronald D.; Thorn, Kurt; Cooke, Roger; Matuska, Marija; Naber, Nariman  
PA The Regents of the University of California, USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001053325 A2 20010726 WO 2001-US2214 20010122  
WO 2001053325 A3 20020307

W: AU, CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

AU 2001031086 A5 20010731 AU 2001-31086 20010122

PRAI US 2000-178054P P 20000124

US 2000-502664 A 20000211

WO 2001-US2214 W 20010122

OS MARPAT 135:149588

AB The present invention features methods for purifying polypeptides of interest using a modified Fluorescein arsenical helix binder (FlAsH) compd. immobilized on a solid support. An exemplary FlAsH target sequence motif is also presented. Examples of modification of the FlAsH compd. which allow immobilization to a solid support are also provided. The present invention also provides DNA constructs for producing a dual

affinity tagged polypeptide and methods for purifn. thereof. Human kinesin constructs C-terminally tagged with the peptide  
WEAAAREACCRECCAR

(specifically chelating with .beta.-alanine-modified FlAsH, prepn. given) were expressed in Escherichia coli and purified using beads contg. .beta.-alanine-modified FlAsH. Protein was eluted using 1,2-ethanedithiol.

L8 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2001:724578 CAPLUS

DN 136:2148

TI Purification, cloning and characterization of a GPI inositol deacylase from Trypanosoma brucei

AU Guther, Maria Lucia Sampaio; Leal, Simone; Morrice, Nicholas A.; Cross, George A. M.; Ferguson, Michael A. J.  
CS Division of Biological Chemistry and Molecular Microbiology, The Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK

SO EMBO Journal (2001), 20(17), 4923-4934  
CODEN: EMJODG; ISSN: 0261-4189

PA Oxford University Press

DT Journal

LA English

AB Inositol \*\*\*acylation\*\*\* is an obligatory step in glycosylphosphatidylinositol (GPI) biosynthesis whereas mature GPI anchors often lack this modification. The GPI anchors of Trypanosoma brucei variant surface glycoproteins (VSGs) undergo rounds of inositol

\*\*\*acylation\*\*\* and deacylation during GPI biosynthesis and the deacylation reactions are inhibited by diisopropylfluorophosphate (DPF). Inositol deacylase was affinity labeled with [3H]DPF and purified. Peptide sequencing was used to clone GPIdAc, which encodes a protein with significant sequence and hydrophathy similarity to mammalian acyloxyacyl hydrolase, an enzyme that removes fatty acids from bacterial lipopolysaccharide. Both contain a signal sequence followed by a saposin domain and a GDSL-lipase domain. GPIdAc-/- trypanosomes were viable in vitro and in animals. Affinity-purified HA-tagged GPIdAc was shown to have inositol deacylase activity. However, total inositol deacylase activity was only reduced in GPIdAc-/- trypanosomes and the VSG GPI anchor was indistinguishable from wild type. These results suggest that there is redundancy in T. brucei inositol deacylase activity and that there is another enzyme whose sequence is not recognizably related to GPIdAc.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:881292 CAPLUS

DN 134:39163

TI Isolation of RNA by differential labeling of the ribose moiety with an affinity label

IN Goldsborough, Andrew Simon

PA Cyclops Genome Sciences Ltd., UK

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 3

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000075302 A2 20001214 WO 2000-GB1684 20000502

WO 2000075302 A3 20010426

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001094626 A1 20011213 WO 2000-GB1683 20000502

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1177281 A2 20020206 EP 2000-929666 20000502

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

EP 1196631 A1 20020417 EP 2000-929665 20000502

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

US 2003039985 A1 20030227 US 2001-11495 20011026

PRAI GB 1999-10154 A 19990430

GB 1999-10156 A 19990430

GB 1999-10157 A 19990430

GB 1999-10158 A 19990430

WO 2000-GB1683 W 20000502

WO 2000-GB1684 W 20000502

AB A method of purifying RNA from a mix of nucleic acids including DNA that makes use of the difference in the sugar moiety of the nucleic acid backbone is described. A sample is treated with a reactant capable of covalently modifying the 2'-OH position of the ribose rings of the RNA under conditions so that a proportion of the 2'-OH positions of the ribose rings bear a substituent followed by sepn. of RNA from other contaminants on the basis of a property of the substituent. The use of alkyl groups to modify the backbone of the RNA for capture on a hydrophobic surface, such as a modified agarose, after salting out with ammonium sulfate is demonstrated.

L8 ANSWER 6 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
AN 1998:496094 BIOSIS  
DN PREV199800496094

TI Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes.  
AU Oelkers, Peter; Behai, Ajay; Cromley, Debra; Billheimer, Jeffrey T.; Sturley, Stephen L. [Reprint author]  
CS Inst. Hum. Nutrition, Columbia Univ. Coll. Physicians Surgeons, 650 W. 168th St., New York, NY 10032, USA  
SO Journal of Biological Chemistry, (Oct. 9, 1998) Vol. 273, No. 41, pp. 26765-26771, print.  
CODEN: JBCHA3. ISSN: 0021-9258.

DT Article  
LA English  
OS Genbank-AF059202; Genbank-AF059203  
ED Entered STN: 18 Nov 1998  
Last Updated on STN: 18 Nov 1998

AB The enzyme acyl coenzyme A:cholesterol acyltransferase 1 (ACAT1) mediates sterol esterification, a crucial component of intracellular lipid homeostasis. Two enzymes catalyze this activity in *Saccharomyces cerevisiae* (yeast), and several lines of evidence suggest multigene families may also exist in mammals. Using the human ACAT1 sequence to screen data bases of expressed sequence tags, we identified two novel and distinct partial human cDNAs. Full-length cDNA clones for these ACAT related gene products (ARGP1) 1 and 2 were isolated from a hepatocyte (HepG2) cDNA library. ARGP1 was expressed in numerous human adult tissues and tissue culture cell lines, whereas expression of ARGP2 was more restricted. In vitro microsomal assays in a yeast strain deleted for both esterification genes and completely deficient in sterol esterification indicated that ARGP2 esterified cholesterol while ARGP1 did not. In contrast to ACAT1 and similar to liver esterification, the activity of ARGP2 was relatively resistant to a histidine active site modifier. ARGP2 is therefore a tissue-specific sterol esterification enzyme which we thus designated ACAT2. We speculate that ARGP1 participates in the coenzyme A-dependent \*\*\*acylation\*\*\* of substrate(s) other than cholesterol. Consistent with this hypothesis, ARGP1, unlike any other member of this multigene family, possesses a predicted diacylglycerol binding motif suggesting that it may perform the last \*\*\*acylation\*\*\* in triglyceride biosynthesis.

L8 ANSWER 7 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
AN 1998:217662 BIOSIS  
DN PREV199800217662

TI Purification, amino acid sequence, and cDNA sequence of a novel calcium-precipitating proteolipid involved in calcification of *Corynebacterium matruchotii*.  
AU van Dijk, S.; Dean, D. D.; Liu, Y.; Zhao, Y.; Chirgwin, J. M.; Schwartz, Z.; Boyan, B. D. [Reprint author]  
CS Audie L. Murphy Meml. Veterans Affairs Med. Cent., San Antonio, TX 78229, USA  
SO Calcified Tissue International, (April, 1998) Vol. 62, No. 4, pp. 350-358.  
print.  
CODEN: CTINDZ. ISSN: 0171-967X.

DT Article  
LA English  
ED Entered STN: 11 May 1998  
Last Updated on STN: 11 May 1998

AB *Corynebacterium matruchotii* is a microbial inhabitant of the oral cavity associated with dental calculus formation. It produces membrane-associated proteolipid capable of inducing hydroxyapatite formation in vitro. This proteolipid was purified from chloroform:methanol extracts by chromatography on Sephadex LH-20 and migrated on SDS-polyacrylamide gel electrophoresis at 6-9 kDa. Removal of covalently attached acyl moieties by methanolic KOH decreased its molecular mass to approximately 5.5 kDa. The amino acid sequence of the apoproteolipid indicated a peptide of 50 amino acids, a calculated molecular weight of 5354 Da, and an isoelectric point of 4.28. Sequence analysis revealed an 8 amino acid sequence with homology to human phosphoprotein phosphatase 2A as well as several potential \*\*\*acylation\*\*\* sites and one phosphorylation site. The purified proteolipid induced calcium precipitation in vitro. Deacylation of the proteolipid by hydroxylamine treatment resulted in >50% loss of calcium-precipitating activity, suggesting that covalently attached lipids are required. Degenerate oligonucleotide primers, based on the amino acid sequence, were used to amplify the gene for the 5.5 kDa proteolipid from total chromosomal DNA of *C. matruchotii* by PCR. A 166 bp cDNA was isolated and sequenced, confirming the amino acid sequence of the

proteolipid. Thus, we have sequenced a unique bacterial proteolipid that is involved in the formation of dental calculus by precipitating Ca<sup>2+</sup> and possibly in transport of inorganic phosphate, necessary for hydroxyapatite formation.

L8 ANSWER 8 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
DUPLICATE 1

AN 1998:509215 BIOSIS  
DN PREV199800509215  
TI 3,4-Dichloroisocoumarin serine protease inhibitor induces DNA fragmentation and apoptosis in susceptible target cells.  
AU Hameed, Arif [Reprint author]; Aslam, Uzma; Ying, Alan J.  
CS Dep. Pathol., Univ. Texas, Southwestern Med. Cent., 5623 Harry Hines Blvd., Dallas, TX 75235, USA  
SO Proceedings of the Society for Experimental Biology and Medicine, (Nov., 1998) Vol. 219, No. 2, pp. 132-137, print.  
CODEN: PSEBAA. ISSN: 0037-9727.

DT Article  
LA English  
ED Entered STN: 18 Dec 1998  
Last Updated on STN: 10 May 1999  
AB 3,4-Dichloroisocoumarin (DCI) inhibition of serine proteases generates reactive intermediates that have been theorized to affect apoptosis. To examine this possibility various target cells were treated with different concentrations of DCI and assessed for intracellular nuclear DNA fragmentation and apoptosis. DCI treatment caused oligonucleosomal DNA fragmentation in cell lines expressing high levels of protease activity (LAK cells, NK-92, CTLT-2, L929, 3T3). This DNA breakdown characteristic of apoptosis occurred in a dose-dependent fashion within 4-6 hr of treatment and was confirmed by electron microscopy. In cell lines expressing low levels of protease activity (unstimulated human peripheral blood mononuclear (PBMN) cells, YAC-1 cells), DCI effectively inhibited protease activity without inducing oligonucleosomal DNA fragmentation. ZN<sup>2+</sup> significantly inhibited DCI-induced DNA degradation. The mixture of DCI and BLT esterase active NK cell lysate triggered \*\*\*DNA\*\*\* fragmentation in \*\*\*isolated\*\*\* YAC-1 nuclei. Degree of DNA fragmentation in YAC-1 nuclei was proportional to the level of BLT esterase activity. Cell lysate protease activity, initially inhibited by DCI \*\*\*acylation\*\*\*, was restored by hydroxylamine deacylation, thus preventing DCI-mediated DNA fragmentation. Our results suggest that DCI treatment of cells expressing high levels of protease activity generates toxic levels of acyl-enzyme intermediates. These intermediates may trigger nuclear DNA breakdown and apoptosis by activating endogenous endonucleases. This effect may compromise the analysis of apoptosis in experimental systems using high concentrations of DCI for extended periods.

L8 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:313904 CAPLUS  
DN 124:334835  
TI Sequence-specific binding oligomers for nucleic acids and their use in antisense strategies with improved duplex stability.  
IN Herewijn, Piet Andre Maurits; Van Aerschot, Arthur Albert Edgard  
PA Stichting Rega VZW, Belg.  
SO PCT Int. Appl., 26 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN,CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 9605213 A1 19960222 WO 1995-EP3248 19950814  
W: AM, AT, AU, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,  
GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,  
MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,  
TM, TT  
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,  
SN, TD, TG  
CA 2196306 AA 19960222 CA 1995-2196306 19950814  
AU 9533845 A1 19960307 AU 1995-33845 19950814  
EP 777676 A1 19970611 EP 1995-930468 19950814  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
CN 1158618 A 19970903 CN 1995-195211 19950814  
HU 77509 A2 19980528 HU 1998-97 19950814  
JP 2000050778 T2 20000516 JP 1996-507032 19950814  
FI 9700598 A 19970212 FI 1997-598 19970212  
NO 9700716 A 19970217 NO 1997-716 19970217  
PRAI EP 1994-202342 19940817  
US 1995-495152 19950628  
WO 1995-EP3248 19950814  
OS MARPAT 124:334835

AB Disclosed are oligomers consisting completely or partially of 1,5-anhydrohexitol nucleoside analogs linked via phosphodiester bridges. Prepn. of 1,5-anhydro-2,3-dideoxy-2-substituted-D-arabino-hexitol nucleoside analogs, their 4,6-O-benzylidene protected derivs., succinylation of the 6-O-protected nucleoside analogs, and the prodn. of the modified oligonucleotides were demonstrated. Stability of the modified oligonucleotides with their complementary antiparallel sequences was also evaluated by dtg, their melting temp. (Tm). Applications of the invention include diagnosis, therapy, \*\*\*DNA\*\*\* modification and \*\*\*isolation\*\*\*, etc.

L8 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1996:309693 CAPLUS

DN 125:2816

TI Histones associated with non-nucleosomal rat ribosomal genes are acetylated while those bound to nucleosome-organized gene copies are not  
AU Mutskov, Vesco J.; Russanova, Valya R.; Dimitrov, Stefan I.; Pashev, Iliya G.

CS Inst. Mol. Biol., Bulgarian Acad. Sci., Sofia, 1113, Bulg.  
SO Journal of Biological Chemistry (1996), 271(20), 11852-11857  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB Acetylation of histones bound to rat rRNA genes has been studied relative to their organization in chromatin, either as canonical nucleosomes, contg. the inactive copies, or as nucleosomal nonrepeating structures, corresponding to the transcribed genes (Conconi, A., Widmer, R. M., Koller, T., and Sogo, J. M. (1989) Cell 57, 753-761). Nuclei from butyrate-treated rat tumor cells were irradiated with a UV laser to cross-link proteins to \*\*\*DNA\*\*\*, and the \*\*\*purified\*\*\* covalent complexes were immunofractionated by an antibody that specifically recognized the acetylated histones. Upon probing with sequences coding for mature rat 28 S RNA, DNA of the antibody-bound complexes was 5-20-fold enriched relative to the total rat DNA. Since the laser cross-links histones to DNA in both active and inactive genes, one cannot distinguish which one of them, or both, are bound to acetylated histones. Alternatively, purified mononucleosomes were immunofractionated, but DNA from the antibody-bound monosomes was not enriched in coding rRNA. Taken together, these results suggest that nucleosome-organized rRNA genes are bound to nonmodified histones and that the acetylated histones are assocd. with the active, anucleosomal gene copies.

L8 ANSWER 11 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

AN 95277370 EMBASE

DN 1995277370

TI Large scale synthesis of p-benzoquinone-2'-deoxycytidine and p-benzoquinone-2'-deoxyadenosine adducts and their site-specific incorporation into DNA oligonucleotides.

AU Chenna A.; Singer B.

CS Donner Laboratory, University of California, Berkeley, CA 94720, United States

SO Chemical Research in Toxicology, (1995) 8/6 (865-874).  
ISSN: 0893-228X CODEN: CRTOEC

CY United States

DT Journal; Article

FS 029 Clinical Biochemistry

052 Toxicology

LA English

SL English

AB Benzene is a carcinogen in rodents and a cause of bone marrow toxicity and leukemia in humans. p-Benzenequinone (p-BQ) is one of the stable metabolites of benzene, as well as of a number of drugs and other chemicals. 2'-Deoxycytidine (dC) and 2'-deoxyadenosine (dA) were allowed to react with p-BQ in aqueous solution at pH 7.4 and 4.5. The yields were considerably higher at pH 4.5 than at pH 7.4, as indicated by HPLC analysis. The desired products were isolated by column chromatography on silica gel or cellulose. Identification was done by FAB-MS, 1H NMR, and UV spectroscopy. The reaction of p-BQ with dC and dA at pH 4.5 produced the exocyclic compounds 3-hydroxy-1,N4-benzetheno-2'-deoxycytidine (p-BQ-dC), and 9-hydroxy-1,N6-benzetheno- 2'-deoxyadenosine (p-BQ-dA), respectively, in a large scale and high yield. These adducts have been previously made in a microgram scale as the 3'- phosphate for 32P-postlabeling studies of their incidence in DNA. The p-BQ-dC and p-BQ-dA adducts have, in addition to the two hydroxyl groups of deoxyribose, one newly formed hydroxyl group at the C-3 or C-9 of the exocyclic base of each product respectively. Incorporation of these adducts into oligonucleotides as the phosphoramidite requires the protection of all three hydroxyl groups in these compounds. The exocyclic hydroxyl on the base has been successfully protected by \*\*\*acetylation\*\*\* after protecting the 5'- and the 3'-hydroxyl groups of the sugar moiety with a 4,4'-dimethoxytrityl group and a cyanoethyl N,N-diisopropylphosphoramidite group, respectively. For the first time, to our knowledge, the fully protected phosphoramidites of p-BQ-dC and p-BQ-dA were prepared and incorporated site-specifically into a series of oligonucleotides. The coupling efficiency was very high (>98%). However, deprotection of the DNA oligomers with ammonia produced only 50% of the desired oligomer containing the adduct. In contrast, when 10% of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in methanol at room temperature was used, only the desired oligomers were detected by HPLC. Thus, by deprotecting the oligomers with methoxide ions (DBU/methanol) and avoiding the use of ammonia, a high yield of modified \*\*\*DNA\*\*\* was obtained. After \*\*\*purification\*\*\* of these oligomers by HPLC, they were hydrolyzed enzymatically and analyzed by HPLC, which confirmed the base composition and the incorporation of the adducts. The mass spectroscopic analysis of the DNA oligomers was confirmed by electrospray MS. These oligomers are now under investigation for their biochemical properties.

L8 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:294129 CAPLUS

DN 122:290591

TI Preparation of carbodiimide-containing biotin derivatives as reagents for detecting point mutation of gene and diagnosis of hereditary disease  
IN Yamamoto, Isamu; Mukai, Tsunehiro  
PA Yamamoto Isamu, Japan  
SO Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKXXAF

DT Patent

LA Japanese

FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI JP 06271581 A2 19940927 JP 1993-80196 19930315  
PRAI JP 1993-80196 19930315  
OS MARPAT 122:290591  
GI

/ Structure 1 in file .gra /

AB The title biotin derivs. (I; R1 = C1-6 alkyl, cycloalkyl; R2 = C1-6 alkylene; R3, R4 = C1-3 alkyl; X = halogen ion), suitable for chem. modification of genes, are prep'd. The presence and position of point mutation in a gene is detd. by (1) mixing for hybridization each complimentary single strand of a normal gene and its corresponding gene assuming the presence of point mutations, (2) reacting the above biotin deriv. I, (3) adsorbing the biotin deriv.-bonded DNA to a agarose column contg. avidin or its analog, (3) eluting the column with a soln. of biotin, and (5) detg. the base sequence of the \*\*\*isolated\*\*\* \*\*\*DNA\*\*\* fragment. Diagnosis of a hereditary disease involves (1) mixing for hybridization each complimentary single strand of a normal gene and its corresponding gene assuming the presence of point mutation, (2) reacting the above biotin deriv. I, and (3) detecting the biotin deriv.-bonded DNA by luminescence or fluorescence using avidin or its analog, which confirms the presence of gene point mutations. Both complimentary single strands of a normal gene and its corresponding gene assuming the presence of point mutation are obtained by cutting genes with a restriction enzyme. The avidin deriv. is a streptavidin-alkali phosphatase conjugate. These carbodiimide-contg. biotin derivs. I react with guanine (G) or thymine (T) of a double stranded DNA having G-T or T-G mismatching. Thus, 260 mg biotin hydrazide was dissolved in 0.5 M NaHCO3 followed by adding a soln. of 520 mg bromoacetic anhydride in dioxane at 0 degree., filtering off the pptd. crystals after 15 min, and recrystn. from H2O to give 227.4 mg N-biotinyl-N'-bromoacetylhydrazine which was stirred with 1-cyclohexyl-3-(3-dimethylaminopropyl)carbodiimide in DMF to give 97% title compd. I [R1 = cyclohexyl, R2 = (CH2)3, R3 = R4 = Me, X = Br-] (II). Aldolase genes were cut out from both plasmid pHAA47 contg. normal A-type aldolase gene and plasmid pHAdA526 contg. A-type aldolase gene from a hemolytic anemia patent but lacking erythrocyte aldolase activity by restriction enzyme Xba and HindIII, resp., sep'd. by a agarose electrophoresis, and each digested by restriction enzyme RsaI into 3 DNA. Both digested genes were heated in a hybridization buffer at 100 degree. for 10 min and left to stand at 42 degree. overnight followed by adjusting the pH to 8.5 and reacting with II at 30 degree. for 30 min. DNA's were sep'd. by pptn. with EtOH, dissolved in H2O, and passed to a avidin agarose column followed by eluting the column with 1 mM aq. biotin to sep. II-bonded DNA. As expected, the 411 bp fragment was recovered and confirmed to contain a mutation with the 386th adenine replaced with guanine in the patient lacking aldolase activity.

L8 ANSWER 13 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

DUPLICATE 2

AN 1994:179968 BIOSIS

DN PREV199491792968

TI Adduct detection by \*\*\*acetylation\*\*\* with (35S)methionine: Analysis of DNA adducts of 4-aminobiphenyl.

AU Sheabar, Fayad Z.; Moringstar, Marshall L.; Wogan, Gerald N. [Reprint author]

CS Div. Toxicol. Dep. Chem., MA Inst. Technol., Cambridge, MA 02139, USA  
SO Proceedings of the National Academy of Sciences of the United States of America, (1994) Vol. 91, No. 5, pp. 1696-1700.

CODEN: PNASA6. ISSN: 0027-8424.

DT Article

LA English

ED Entered STN: 26 Apr 1994

Last Updated on STN: 27 Apr 1994

AB Reaction of synthetic N-(2'-deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP) with t-butoxycarbonyl-L-(35S)methionine, N-hydroxysuccinimidyl ester (35S-labeled TBM-NHS), under optimized conditions produced mono-, bis-, and tris-TBM-acylated nucleosides that were separable by HPLC. Reaction of different amounts of N-(2'-deoxy-1',2'(3H)guanosin-8-yl)-4-aminobiphenyl ((3H)dGuo-8-ABP) with 35S-labeled TBM-NHS established that total 35S content of acylated products was linearly related to adduct concentration ( $r = 0.992$ ) over the range of 10 fmol to 30.6 pmol. Additionally, the N-(deoxyguanosin-8-yl)-4-(3H)aminobiphenyl (dGuo-8(3H)ABP) adduct was \*\*\*isolated\*\*\* from calf thymus \*\*\*DNA\*\*\* adducted in vitro and from rat liver DNA adducted in vivo and similarly reacted with 35S-labeled TBM-NHS. \*\*\*Acylation\*\*\* products of dGuo-8-ABP from all three sources showed HPLC retention times identical to those of authentic TBM-dGuo-8-ABP, and 35S incorporation into acylated products was linearly related to amount of adduct reacted. These results indicate that the procedure, to which we have referred as adduct detection

by \*\*\*acylation\*\*\* with methionine (ADAM), has potential applicability as an analytical procedure for detection and quantification of DNA adducts in human tissues in the molecular epidemiology of cancer.

L8 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1991:82555 CAPLUS

DN 114:82555

TI Peptide and oligonucleotide purification using immunoaffinity techniques  
IN Lewis, William; Stout, Jay; Van Heeke, Gino; Wylie, Dwane E.; Schuster, Sheldon M.; Wagner, Fred W.; Coolidge, Thomas R.

PA University of Nebraska, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9006936 A1 19900628 WO 1989-US5737 19891221  
W: AU, DK, FI, HU, JP, KR, NO, SU  
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE  
US 5049656 A 19910917 US 1988-288009 19881221  
CA 2006334 AA 19900621 CA 1989-2006334 19891221  
AU 9048494 A1 19900710 AU 1990-48494 19891221  
AU 645964 B2 19940203  
EP 449890 A1 19911009 EP 1990-901956 19891221  
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE  
JP 4504409 T2 19920806 JP 1990-502101 19891221  
US 5221736 A 19930622 US 1989-454372 19891221  
CA 2018377 AA 19910621 CA 1990-2018377 19900606  
DK 9101203 A 19910821 DK 1991-1203 19910620  
US 5464759 A 19951107 US 1993-18100 19930217  
PRAI US 1988-288009 19881221  
US 1989-454372 19891221  
WO 1989-US5737 19891221

AB Sequentially synthesized peptides and oligonucleotides are purified by affinity techniques which involve capping the peptides with N-terminus capping agents or the oligonucleotides with 5'-terminus capping agents and contacting the capped peptides or oligonucleotides with (immobilized) affinity agents that are selective for the corresponding capping agents. The capping agents and their corresponding affinity agents constitute affinity pairs which are preferably selected from, (1) an antigenic capping agent with an antibody, e.g. an antibody for peptides with an N-terminus antigenic capping agent such as phthalic anhydride, BzCl, or naphthoyl halide, (2) an enzymic substrate, inhibitor or cofactor capping agent with its complementary enzyme affinity agent, e.g. anthranilic acid its derivs. with anthranilate synthase, (3) a vitamin or sugar capping agent with its complementary apoenzyme or lactic affinity agent, e.g. riboflavin with a glucose oxidase, and (4) a covalent bond forming capping agent with its complementary covalent bond reactant affinity agent, e.g. acrylic acid and its deriv. with a diene or acrylamide deriv. A magnetic N-terminus capping agent such as ferrocene derivs. can also be used to cap failed peptides of the sequential synthesis and the failed peptide sequences are removed by a magnet. Thus, bradykinin, i.e. H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH, was prep'd. by the solid phase method on a phenylacetamidomethylpolystyrene resin and was acylated with dinitrobenzoyl (DNB) chloride in DMF to give, after resin cleavage, a crude DNB-capped bradykinin which was purified by immunoaffinity chromatog. on a column contg. Sepharose-bound rabbit anti-DNB antibody. Also prep'd. was 5'-GAATTCGATCCGAATT-3' capped with 3-nitrophthalic anhydride (NPA), which was purified on an immunoaffinity column of rabbit anti-NPA antibody bound to a Sepharose gel. The oligonucleotides are useful as DNA probes in the polymerase chain reaction technique and for diagnosis or treatment of genetic disorders in humans or animals.

L8 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1977:479370 CAPLUS

DN 87:79370

TI Metabolic activation of 4-nitroquinoline 1-oxide and its binding to nucleic acid

AU Tada, Mitsuhiro; Tada, Mariko

CS Res. Inst., Aichi Cancer Cent., Nagoya, Japan

SO Fundam. Cancer Prev., Proc. Int. Symp. Princess Takamatsu Cancer Res. Fund, 6th (1976), Meeting Date 1975, 217-28. Editor(s). Magee, Peter N.; Takayama, Shozo; Sugimura, Takashi. Publisher: Univ. Tokyo Press, Tokyo, Japan.

CODEN: 35VGAV

DT Conference

LA English

GI

/ Structure 2 in file .gra /

AB 4-Hydroxyaminoquinoline 1-oxide (I) [4637-56-3], the reduced metabolite of 4-nitroquinoline 1-oxide (II) [56-57-5] was bound to nucleic acid in vitro via catalysis by seryl-tRNA synthetase [9023-48-7] from yeast. I was activated through \*\*\*acylation\*\*\* by seryl-AMP formed as part of the intermediate complex in the seryl-tRNA synthetase reaction. The isolated seryl-AMP-enzyme complex or synthetic seryl-AMP activated I. The reactive metabolite produced in the reaction may be assumed to be an aminoacylated deriv. which may attack purine residues in nucleic acid. Among the

aminoacyl-tRNA synthetases in bakers' yeast cells, only seryl-tRNA synthetase had the ability to activate I. Seryl- and prolly-tRNA synthetases in rat liver and seryl- and phenylalanyl-tRNA synthetases in Escherichia coli may participate in the activation of I. In the *in vivo* enzyme reaction, I bound to poly(G) and poly(A) to give rise to 3 kinds of adducts (2 quanine adducts and 1 adenine adduct) which were identical with the major products found in the RNA isolated from II-treated cells. In \*\*\*DNA\*\*\* \*\*\*isolated\*\*\* from II-treated cells, an addnl. adduct was found other than these 3. The chem. structure of the adenine adduct is proposed as either 3-(N6-adenyl)- or 3-(N1-adenyl)-4-aminoquinoline 1-oxide.

L8 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1969:409810 CAPLUS

DN 71:9810

TI Enzymic synthesis of deoxyribonucleic acid. XXVII. Chemical modifications of deoxyribonucleic acid polymerase

AU Jovin, Thomas M.; Englund, Paul T.; Kornberg, Arthur

CS Sch. of Med., Stanford Univ., Stanford, CA, USA

SO Journal of Biological Chemistry (1969), 244(11), 3009-18

CODEN: JBCHA; ISSN: 0021-9258

DT Journal

LA English

AB The \*\*\*purified\*\*\* Escherichia coli \*\*\*DNA\*\*\* polymerase (I) contains a single SH group which reacts with Hg(II) to produce either a monomer contg. a single Hg atom or a dimer of 2 protein mols. joined by a Hg atom. Both forms retain full I and exonuclease activities, implying that the SH group is relatively exposed and not essential for enzymic activity. The acylating agent, N-carboxymethylisatoic anhydride, reacts with an observed max. of 11 sites on I to form a highly fluorescent deriv. with altered functional properties. Only 0.2% of original I activity but 920% of the exonuclease activity are observed at pH 7.4 with DNA as primer or substrate. Measurements of release of inorg. pyrophosphate and binding of triphosphates indicate that the predominant effect of this acylating agent is to cause a marked redn. in the affinity for deoxyribonucleoside triphosphate substrates, but concomitant changes in the interaction of I with polynucleotides are probably also involved. The data are discussed in terms of a model in which the several activities of I are catalyzed at the same active center, which is differentiated into phys. distinct sites.

=> d his

(FILE 'HOME' ENTERED AT 16:35:38 ON 25 NOV 2003)

FILE 'BIOSIS, EMBASE, CAPLUS' ENTERED AT 16:35:43 ON 25 NOV 2003

L1 65109 S (ISOLAT? OR PURIF?) (3A) DNA

L2 0 S L1 AND FISH SPERMATOGONIUM

L3 0 S L1 AND FISH SPERMAT?

L4 2314 S L1 AND SPERMAT?

L5 1 S L4 AND (SODIUM NITRITE OR SODIUM CARBONITE OR SODIUM PHOSPHATE)

L6 0 S L4 AND ACYLATION

L7 20 S L1 AND ACYLATION

L8 16 DUP REM L7 (4 DUPLICATES REMOVED)

L9 0 S L6 AND HIGH SALT

L10 0 S L8 AND HIGH SALT

=> s L8 and sodium

L11 0 L8 AND SODIUM

=> d his

(FILE 'HOME' ENTERED AT 16:35:38 ON 25 NOV 2003)

FILE 'BIOSIS, EMBASE, CAPLUS' ENTERED AT 16:35:43 ON 25 NOV 2003

L1 65109 S (ISOLAT? OR PURIF?) (3A) DNA

L2 0 S L1 AND FISH SPERMATOGONIUM

L3 0 S L1 AND FISH SPERMAT?

L4 2314 S L1 AND SPERMAT?

L5 1 S L4 AND (SODIUM NITRITE OR SODIUM CARBONITE OR SODIUM PHOSPHATE)

L6 0 S L4 AND ACYLATION

L7 20 S L1 AND ACYLATION

L8 16 DUP REM L7 (4 DUPLICATES REMOVED)

L9 0 S L6 AND HIGH SALT

L10 0 S L8 AND HIGH SALT

L11 0 S L8 AND SODIUM

=>

--Logging off of STN--

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST            84.11    84.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE  
TOTAL

CA SUBSCRIBER PRICE            ENTRY    SESSION  
                                  -6.51    -6.51

STN INTERNATIONAL LOGOFF AT 16:42:36 ON 25 NOV 2003